The Netherlands Cancer Institute
OrganisationROR
People
Junior group leader, 11 Sept 2026, reporter.nih.gov
Trials
Phase 2, Not yet recruiting, 2026, 80 people, 25 Aug 2026, clinicaltrials.gov
Phase 3, Recruiting, 2025, 408 people, 21 Mar 2025, clinicaltrials.gov
Phase 2, Recruiting, 2025, 41 people, 12 Feb 2025, clinicaltrials.gov
Phase 2, Recruiting, 2024, 27 people, 9 Apr 2024, clinicaltrials.gov
Phase 2/3, Recruiting, 2024, 133 people, 26 Feb 2024, clinicaltrials.gov
Phase 2, Recruiting, 2024, 98 people, 15 Jun 2023, clinicaltrials.gov
Phase 1/2, Recruiting, 2022, 24 people, 22 Feb 2022, clinicaltrials.gov
Phase 2, Completed, 2020, 50 people, 6 Nov 2020, clinicaltrials.gov
Phase 1, Terminated, 2018, 18 people, 27 Feb 2020, clinicaltrials.gov
Phase 2, Recruiting, 2020, 51 people, 10 Dec 2019, clinicaltrials.gov
Phase 2, Recruiting, 2020, 12 people, 13 Nov 2019, clinicaltrials.gov
Phase 2, Recruiting, 2020, 52 people, 12 Nov 2019, clinicaltrials.gov
Phase 2, Terminated, 2018, 1 person, 25 Feb 2019, clinicaltrials.gov
Phase 3, Active, not recruiting, 2020, 538 people, 11 Dec 2018, clinicaltrials.gov
Phase 2, Active, not recruiting, 2018, 20 people, 28 Feb 2018, clinicaltrials.gov
Phase 2, Terminated, 2017, 23 people, 10 May 2017, clinicaltrials.gov
Phase 1/2, Completed, 2017, 33 people, 24 Apr 2017, clinicaltrials.gov
Phase 2, Recruiting, 2017, 353 people, 20 Jan 2017, clinicaltrials.gov
Phase 2, Active, not recruiting, 2017, 207 people, 13 Oct 2016, clinicaltrials.gov
Phase 2, Recruiting, 2016, 1,550 people, 5 Oct 2016, clinicaltrials.gov
Grants and prizes
R37, Quantitative background parenchymal enhancement, measured on contrast-enhanced mammogram, as a novel marker of breast cancer risk, R37CA284134, US$62.4k, 2024–2027, 11 Sept 2026, reporter.nih.gov